{"id":"https://openalex.org/W2579219442","doi":"https://doi.org/10.1182/blood.v114.22.755.755","title":"A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2V617F Allele Burden.","display_name":"A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2V617F Allele Burden.","publication_year":2009,"publication_date":"2009-11-20","ids":{"openalex":"https://openalex.org/W2579219442","doi":"https://doi.org/10.1182/blood.v114.22.755.755","mag":"2579219442"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v114.22.755.755","doi":"https://doi.org/10.1182/blood.v114.22.755.755","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v114.22.755.755","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5024612499","display_name":"Animesh Dev Pardanani","orcid":"https://orcid.org/0000-0002-9084-4148","observed_orcids":["https://orcid.org/0000-0002-9084-4148"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Animesh D. Pardanani","raw_affiliation_strings":["Hematology, Mayo Clinic, Rochester, MN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology, Mayo Clinic, Rochester, MN, USA,","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065621786","display_name":"Jason R. Gotlib","orcid":"https://orcid.org/0000-0001-8253-6156","observed_orcids":["https://orcid.org/0000-0001-8253-6156"]},"institutions":[{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jason R Gotlib","raw_affiliation_strings":["Stanford University, Palo Alto, CA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Stanford University, Palo Alto, CA, USA,","institution_ids":["https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030193536","display_name":"Catriona H. M. Jamieson","orcid":"https://orcid.org/0000-0001-8057-6613","observed_orcids":["https://orcid.org/0000-0001-8057-6613"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Catriona Jamieson","raw_affiliation_strings":["Department of Medicine and Moores Cancer Center, University of California San Diego, La Jolla, CA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine and Moores Cancer Center, University of California San Diego, La Jolla, CA, USA,","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015101485","display_name":"J\u00f6rge E. Cortes","orcid":"https://orcid.org/0000-0002-8636-1071","observed_orcids":["https://orcid.org/0000-0002-8636-1071"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jorge Cortes","raw_affiliation_strings":["Leukemia Dept., The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia Dept., The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011529063","display_name":"Moshe Talpaz","orcid":"https://orcid.org/0000-0003-3361-3981","observed_orcids":["https://orcid.org/0000-0003-3361-3981"]},"institutions":[{"id":"https://openalex.org/I27837315","display_name":"University of Michigan","ror":"https://ror.org/00jmfr291","country_code":"US","type":"education","lineage":["https://openalex.org/I27837315"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Moshe Talpaz","raw_affiliation_strings":["Comprehensive Cancer Ctr., University of Michigan, Ann Arbor, MI, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Comprehensive Cancer Ctr., University of Michigan, Ann Arbor, MI, USA,","institution_ids":["https://openalex.org/I27837315"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071023119","display_name":"Richard Maury Stone","orcid":"https://orcid.org/0000-0002-7526-2633","observed_orcids":["https://orcid.org/0000-0002-7526-2633"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Richard Stone","raw_affiliation_strings":["Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015130241","display_name":"Michael H. Silverman","orcid":"https://orcid.org/0000-0002-6651-646X","observed_orcids":["https://orcid.org/0000-0002-6651-646X"]},"institutions":[{"id":"https://openalex.org/I4405267125","display_name":"Xiamen Innovax Biotech Co., Ltd. (China)","ror":"https://ror.org/01a51nj96","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267125"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Michael H Silverman","raw_affiliation_strings":["Biostrategics Consulting Ltd., Marblehead, MA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biostrategics Consulting Ltd., Marblehead, MA,","institution_ids":["https://openalex.org/I4405267125"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073281082","display_name":"Jolene S. Shorr","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Jolene Shorr","raw_affiliation_strings":["TargeGen Inc., San Diego, CA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"TargeGen Inc., San Diego, CA, USA,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113728001","display_name":"Dwight Gary Gilliland","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. Gary Gilliland","raw_affiliation_strings":["Merck Research Laboratories, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Research Laboratories, Boston, MA, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5016216479","display_name":"Ayalew Tefferi","orcid":"https://orcid.org/0000-0003-4605-3821","observed_orcids":["https://orcid.org/0000-0003-4605-3821"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ayalew Tefferi","raw_affiliation_strings":["Hematology, Mayo Clinic, Rochester, MN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology, Mayo Clinic, Rochester, MN, USA,","institution_ids":["https://openalex.org/I1330342723"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":9,"corresponding_author_ids":["https://openalex.org/A5015130241","https://openalex.org/A5065621786","https://openalex.org/A5071023119","https://openalex.org/A5073281082"],"corresponding_institution_ids":["https://openalex.org/I4210117453","https://openalex.org/I4405267125","https://openalex.org/I97018004"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":5.1341,"has_fulltext":false,"cited_by_count":40,"citation_normalized_percentile":{"value":0.957498,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"114","issue":"22","first_page":"755","last_page":"755"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/jak2-inhibitors","display_name":"JAK2 inhibitors","score":0.953000009059906},{"id":"https://openalex.org/keywords/myelofibrosis","display_name":"myelofibrosis","score":0.9789999723434448},{"id":"https://openalex.org/keywords/jak2-v617f-allele-burden","display_name":"JAK2 V617F allele burden","score":0.875},{"id":"https://openalex.org/keywords/primary-myelofibrosis","display_name":"primary myelofibrosis","score":0.9240000247955322},{"id":"https://openalex.org/keywords/post-polycythemia-vera-myelofibrosis","display_name":"post-polycythemia vera myelofibrosis","score":0.902999997138977},{"id":"https://openalex.org/keywords/post-essential-thrombocythemia-myelofibrosis","display_name":"post-essential thrombocythemia myelofibrosis","score":0.9399999976158142},{"id":"https://openalex.org/keywords/spleen-size-reduction","display_name":"spleen size reduction","score":0.8080000281333923},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.7940000295639038},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.7770000100135803},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.9900000095367432},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.5889999866485596}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8399323225021362},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.7456164360046387},{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.6958410739898682},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.6273748278617859},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5974165797233582},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.5828901529312134},{"id":"https://openalex.org/C2777910003","wikidata":"https://www.wikidata.org/wiki/Q1707292","display_name":"Asymptomatic","level":2,"score":0.5781302452087402},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.5187716484069824},{"id":"https://openalex.org/C2780852908","wikidata":"https://www.wikidata.org/wiki/Q127076","display_name":"Vomiting","level":2,"score":0.5111339688301086},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.5058924555778503},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.38775011897087097},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.1483757197856903}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v114.22.755.755","doi":"https://doi.org/10.1182/blood.v114.22.755.755","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v114.22.755.755","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2105496815","https://openalex.org/W2561728622","https://openalex.org/W2592214846","https://openalex.org/W2590655325","https://openalex.org/W2588005189","https://openalex.org/W2536171864","https://openalex.org/W2123633897","https://openalex.org/W2550982834","https://openalex.org/W1995981641","https://openalex.org/W1986595955"],"abstract_inverted_index":{"Abstract":[0,1],"755":[2],"Background:":[3],"TG101348":[4,113,285,543,584],"is":[5,15,265,274,286],"a":[6,20,39,133,146,207,440,453,502,517],"potent,":[7],"orally":[8],"bioavailable,":[9],"JAK2-selective":[10],"small":[11],"molecule":[12],"inhibitor,":[13],"that":[14,70,92,355],"currently":[16,244],"being":[17],"evaluated":[18],"in":[19,106,116,164,171,300,305,397,409,417,443,479,490,506,549,575,589],"Phase":[21],"I":[22],"study":[23,204],"for":[24,477,566],"the":[25,31,74,138,165,172,246,290,413,465,487,507,586],"treatment":[26,144,220,281,511],"of":[27,110,148,210,230,235,322,327,337,391,464,530,583],"myelofibrosis.":[28,552,590],"Data":[29,602],"from":[30,55,137,603],"dose":[32,77,139,147,166,173,248],"escalation":[33,167],"cohort":[34,141],"(n=28;":[35],"30-800mg":[36],"administered":[37],"as":[38],"single":[40],"daily":[41],"dose)":[42],"showed":[43],"dose-linear":[44],"plasma":[45],"exposure,":[46],"with":[47,132,424,551,572],"mean":[48],"elimination":[49],"T1/2":[50],"at":[51,145,203,245,269,282,294,316,341,383,387,393,406,426,436,457,470,483,512],"steady":[52],"state":[53],"ranging":[54],"20":[56],"to":[57,222,263,431,449,545,581],"52":[58],"hours.":[59],"The":[60,81,239,259,335],"dose-limiting":[61],"toxicity":[62,223],"was":[63,71,79,195,298,405,495,524],"asymptomatic":[64,374],"grade":[65],"3":[66,185,389,394],"or":[67,96,233,270,358,528],"4":[68,448],"amylasemia/lipasemia":[69],"reversible,":[72],"and":[73,102,108,122,169,184,197,256,302,325,331,373,474,505,539,554,561,579],"maximum":[75],"tolerated":[76,548],"(MTD)":[78],"680mg.":[80],"most":[82],"frequent":[83],"non-hematological":[84,362],"toxicities":[85,363],"were":[86,93,104,189,200,356,475],"mild":[87,344],"nausea,":[88],"vomiting,":[89],"and/or":[90,351],"diarrhea":[91,352],"easily":[94,359],"controlled":[95],"resolved":[97],"spontaneously.":[98],"Grade":[99],"3/4":[100],"neutropenia":[101,297],"thrombocytopenia":[103,304],"observed":[105,299,559],"14%":[107],"25%":[109],"patients,":[111],"respectively.":[112,334],"had":[114,179,452,501,516],"activity":[115,582],"reducing":[117],"spleen":[118,193,399,414],"size,":[119],"leukocyte":[120,555],"count,":[121],"JAK2V617F":[123],"(VF)":[124],"allele":[125,481,493,577],"burden.":[126],"Here,":[127],"we":[128],"present":[129],"updated":[130],"results":[131],"focus":[134],"on":[135],"data":[136],"confirmation":[140,174],"who":[142,292,339,381,434,509],"initiated":[143],"680mg/day.":[149],"Results:":[150],"Fifty":[151],"nine":[152],"patients":[153,178,199,217,242,278,291,310,328,338,380,423,468,499,550],"(median":[154,318],"age=66":[155],"years;":[156],"range":[157,320,403,429],"43-86)":[158],"have":[159,218,385,438,500,515],"been":[160],"treated":[161],"\u2013":[162],"28":[163],"phase,":[168],"31":[170],"phase.":[175],"Overall,":[176,462],"44":[177],"PMF,":[180],"12":[181,211],"post-PV":[182],"MF,":[183],"post-ET":[186],"MF;":[187],"86%":[188],"VF-positive.":[190],"Median":[191],"palpable":[192,398],"size":[194,400],"18cm":[196],"22":[198,410],"RBC":[201,314],"transfusion-requiring":[202],"enrollment.":[205],"After":[206],"median":[208,488],"follow-up":[209,460],"weeks":[212],"(range":[213,447],"<1-76),":[214],"18":[215],"(31%)":[216],"discontinued":[219],"due":[221],"(n=7;":[224],"thrombocytopenia=3,":[225],"neutropenia=1),":[226],"comorbidities":[227],"(n=5),":[228],"withdrawal":[229],"consent":[231],"(n=4),":[232],"non-compliance/lack":[234],"response":[236,478],"(1":[237,346,349],"each).":[238],"remaining":[240],"41":[241],"are":[243,557,570],"following":[247],"levels:":[249],"680mg":[250],"(n=14),":[251],"520-600mg":[252],"(n=16),":[253],"360-440mg":[254],"(n=10),":[255],"240mg":[257],"(n=1).":[258],"cumulative":[260],"drug":[261],"exposure":[262,268],"date":[264],"362":[266],"patient-months;":[267],"above":[271],"MTD":[272],"(\u2265680mg)":[273],"154":[275],"patient-months.":[276],"Forty":[277],"(68%)":[279],"started":[280,293,340,382,435,510],"\u2265680mg.":[283],"Toxicity:":[284],"well":[287,547],"tolerated.":[288],"Of":[289,520],"\u2265680mg,":[295,513],"Gr3/4":[296,303],"15/0%":[301],"20/10%.":[306],"Twenty":[307],"four":[308],"(60%)":[309],"did":[311],"not":[312],"require":[313],"transfusions":[315],"baseline":[317,427],"Hgb=9.6g/dL;":[319],"7.4-13.1);":[321],"these,":[323],"42%":[324],"8%":[326],"developed":[329,343],"Gr3":[330],"Gr4":[332],"anemia,":[333],"majority":[336],"\u2265680mg":[342,384,437],"nausea":[345],"Gr3),":[347,350],"vomiting":[348],"(3":[353],"Gr3)":[354],"self-limited":[357],"controlled.":[360],"Other":[361],"included":[364],"Gr1/2":[365,368],"transaminitis":[366],"(38%),":[367,372],"serum":[369],"creatinine":[370],"elevation":[371],"hyperlipasemia":[375],"(33%).":[376],"Efficacy:":[377],"Thirty":[378],"three":[379],"completed":[386,469],"least":[388,407,471],"cycles":[390],"treatment;":[392],"months,":[395],"reduction":[396,442],"(baseline":[401],"median=18cms;":[402],"6-32)":[404],"50%":[408],"(67%)":[411],"patients;":[412],"became":[415],"non-palpable":[416],"9":[418],"(27%)":[419],"patients.":[420,567],"All":[421],"21":[422,497],"leukocytosis":[425],"(WBC":[428],"11":[430],"203":[432],"\u00d7109/L)":[433],"experienced":[439],"marked":[441],"their":[444,458],"WBC":[445,455],"count":[446,456],"90);":[450],"70%":[451],"normal":[454],"last":[459,484],"visit.":[461],"48":[463],"51":[466],"VF-positive":[467],"1":[472],"cycle":[473],"evaluable":[476],"VF":[480,576],"burden;":[482],"available":[485],"follow-up,":[486],"decrease":[489,574],"granulocyte":[491],"mutant":[492],"burden":[494,578],"48%;":[496],"(44%)":[498],"\u226550%":[503,518],"reduction,":[504],"group":[508],"48%":[514],"reduction.":[519],"those":[521],"evaluable,":[522],"there":[523],"clinically":[525],"significant":[526,573],"benefit":[527,565],"resolution":[529],"constitutional":[531],"symptoms,":[532],"including":[533],"early":[534],"satiety,":[535],"fatigue,":[536],"cough,":[537],"pruritus,":[538],"night":[540],"sweats.":[541],"Conclusions:":[542],"continues":[544],"be":[546,608],"Spleen":[553],"responses":[556,569],"frequent,":[558],"early,":[560],"produce":[562],"substantial":[563],"clinical":[564,605],"These":[568],"associated":[571],"point":[580],"against":[585],"malignant":[587],"clone":[588],"Disclosures:":[591],"Pardanani:":[592],"TargeGen:":[593,621],"Research":[594,597,611,614,617,622,625,628,644],"Funding;":[595,615,618,623],"Cytopia:":[596],"Funding.":[598,612,626,629,645],"Off":[599],"Label":[600],"Use:":[601],"ongoing":[604],"trial":[606],"will":[607],"presented.":[609],"Gotlib:TargeGen:":[610],"Jamieson:Merck:":[613],"Pfizer:":[616],"Wintherix:":[619],"Consultancy;":[620],"Celgene:":[624],"Cortes:Targegen:":[627],"Stone:Cephalon:":[630],"ad":[631],"hoc":[632],"advisory":[633],"board.":[634],"Silverman:TargeGen:":[635],"Consultancy.":[636],"Shorr:TargeGen:":[637],"Employment,":[638],"Equity":[639],"Ownership.":[640],"Gilliland:Merck:":[641],"Employment.":[642],"Tefferi:TargeGen:":[643]},"counts_by_year":[{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-01-26T00:00:00"}